EQRx, Inc.

NasdaqGM:EQRX 주식 보고서

시가총액: US$1.1b

EQRx 과거 수익 실적

과거 기준 확인 0/6

EQRx's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 17.4% annually.

주요 정보

-12.3%

수익 성장률

98.2%

EPS 성장률

Biotechs 산업 성장17.0%
매출 성장률n/a
자기자본 수익률-22.2%
순이익n/a
최근 수익 업데이트30 Sep 2023

최근 과거 실적 업데이트

업데이트 없음

Recent updates

We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

Jul 25
We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

Feb 22
EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

Nov 08
We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs

Aug 28

 EQRx GAAP EPS of -$0.17 beats by $0.03

Aug 11

Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

Jul 24
Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

Apr 08
We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

Dec 24
EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

수익 및 비용 분석

EQRx 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqGM:EQRX 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 230-260104204
30 Jun 230-263114240
31 Mar 230-272124244
31 Dec 220-169129227
30 Sep 220-146138211
30 Jun 220-100121179
31 Mar 220-53102153
31 Dec 210-10080116
30 Sep 210-27950229
30 Jun 210-29640256
31 Mar 210-26932237
31 Dec 200-25027223

양질의 수익: EQRX is currently unprofitable.

이익 마진 증가: EQRX is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: EQRX is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

성장 가속화: Unable to compare EQRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: EQRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


자기자본 수익률

높은 ROE: EQRX has a negative Return on Equity (-22.23%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기